Cagrilintide is a next-generation, long-acting amylin analogue developed for the treatment of obesity and overweight-related conditions. It mimics the action of the natural hormone amylin to regulate appetite and food intake, making it a powerful tool in chronic weight management therapies.

Key Benefits:

• Appetite Suppression: Acts on the central nervous system to promote satiety and reduce food intake.

• Weight Reduction: Clinically proven to support significant and sustained weight loss when used in combination with GLP-1 receptor agonists.

• Long-Acting Formula: Designed for once-weekly dosing, improving patient compliance and treatment outcomes.

• Synergistic Therapy: Frequently studied in combination with semaglutide or liraglutide for enhanced effects.

Applications:

• Obesity Treatment

• Overweight Management in individuals with comorbidities such as type 2 diabetes or hypertension

• Pharmaceutical R&D for metabolic disorders